
ORMP
Oramed Pharmaceuticals develops oral drug delivery technologies and therapeutics, with a focus on treatments for metabolic and gastrointestinal diseases. The firm is in early-to-mid stage development, pursuing oral formulations of drugs that are typically administered by injection or other routes. Oramed also holds financial investments in real estate projects and warrants in other biotech entities.